One simple idea — leave the messenger in the synapse a little longer — built most of modern psychiatry.
Block the pumps that clear serotonin, noradrenaline, and dopamine from the synapse, and you raise their signal. That single mechanism underlies the SSRIs, the SNRIs, bupropion, atomoxetine — and now centanafadine, a first‑in‑class triple reuptake inhibitor whose approval reopened an old question: can a drug work like a stimulant without being liked like one?
When a neuron fires, it releases a monoamine — serotonin, noradrenaline, or dopamine — into the synapse. Milliseconds later, a transporter protein on the sending neuron pumps most of it back in, ending the signal. That recycling step is called reuptake.1
A reuptake inhibitor jams that pump. The neurotransmitter lingers, and its signal is amplified and prolonged. Which transporter a drug blocks — the serotonin transporter (SERT), the noradrenaline transporter (NET), or the dopamine transporter (DAT) — is what defines its class and its clinical personality.2
The idea grew out of the monoamine hypothesis of mood and attention: too little signalling in these systems tracks with depression and attentional dysfunction, and restoring it helps.1
Each family is defined by the transporters it blocks — and each carries a distinct efficacy, side‑effect, and abuse profile that follows directly from that selectivity.
Fluoxetine, sertraline, escitalopram. First‑line for depression, anxiety, and OCD. Broadly safe; onset over weeks, with sexual dysfunction and early GI effects the usual trade‑offs.
Venlafaxine, duloxetine, desvenlafaxine. Depression, anxiety, and chronic pain. The noradrenergic component adds energy and analgesia — and, at higher doses, blood‑pressure effects.
Marketed as Wellbutrin for depression and Zyban for smoking cessation. Energising, weight‑neutral, and without the sexual side effects of SSRIs; it lowers the seizure threshold at high doses.3
Strattera: the first non‑stimulant approved for ADHD. No abuse liability and no controlled‑substance scheduling, but generally less effective than stimulants, with a slow onset and a pediatric suicidality warning.4
The first drug to block SERT, NET, and DAT together to reach market. Approved for ADHD in 2026, it aims to combine stimulant‑like breadth with a non‑stimulant‑like abuse profile — the subject of the rest of this briefing.
Developed by Otsuka and approved by the FDA on 24 July 2026 as Simtriyo, centanafadine is the first norepinephrine‑dopamine‑serotonin reuptake inhibitor (NDSRI) for ADHD in adults and children aged six and older.5,11 Its affinity is strongest at NET, then DAT, then SERT — extending reuptake pharmacology to serotonin, a departure from stimulants and other non‑stimulants.9,12
A drug's abuse potential tracks how fast, and how pleasurably, it raises dopamine in the striatum. Reuptake inhibitors do it slowly.
In a human abuse‑liability study, immediate‑release centanafadine produced lower “drug liking” than the Schedule II stimulants d‑amphetamine and lisdexamfetamine.10
At high doses the experience turned actively aversive — nausea, vomiting, and dysphoria — rather than euphoric, the opposite of a reinforcing drug.10
Because it still inhibits DAT, the FDA label carries a boxed warning for abuse potential — alongside one for suicidal ideation in pediatric patients — with DEA scheduling pending.15,16
The tension is the story: mechanism and abuse‑liability data argue for low reinforcement, while regulators apply stimulant‑class caution until real‑world use confirms it.
Adding dopamine to the serotonin‑noradrenaline template is the through‑line of a new wave of triple reuptake inhibitors — pursued for depression, anhedonia, and other disorders of low monoamine tone, on the bet that the extra dopamine broadens efficacy without a stimulant's liabilities.8
Reference numbering follows first citation in the text. Regulatory and scheduling status reflects public disclosures through mid‑2026 and is subject to change.